This is a Phase II, single-arm study to evaluate the efficacy, safety, and PK of oral linperlisib (YY-20394) monotherapy in adult patients with R/R Peripheral T/NK Cell Lymphoma. The study will be conducted at approximately 15 sites in United States.
1 Primary · 11 Secondary · Reporting Duration: Throughout the study for approximately 2 years
97 Total Participants · 1 Treatment Group
Primary Treatment: YY-20394 · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: